About Anti-PEG
Anti-PEG antibodies were invented in the Institute of Biomedical Sciences at Academia Sinica.
For this reason, our antibodies are sometimes referred to as "Sinica" anti-PEG antibodies.
Academia Sinica was founded in 1928 and remains one of the premiere research facilities in Taiwan.
Academia Sinica is located in the eastern side of Taipei, the capital city of Taiwan.
History
In 1999, we reported the first monoclonal antibodies (E11 and AGP3) with specificity for PEG (Bioconjugate Chem. 10: 520-528, 1999).
AGP3 was used to accelerate the development of Pegasys, a PEGylated form of interferon-alpha-2a (Bioconjugate Chem., 12:195-202., 2001 and Expert Opin Drug Deliv. 6:1-16, 2009).
Since that time, we have developed a range of anti-PEG monoclonal antibodies, which have been used by more than 280 well-known universities and international pharmceutical and biotechnolgy companies to analyze and develop PEGylated medicines.
We continue to develop and research various applications of anti-PEG antibodies including measurement of PEGylated compounds and nanoparticles, bi-specific antibodies for targeted delivery of PEGylated nanocarriers, development of human anti-PEG antibodies and measurement of anti-PEG antibodies in humans.